IASLC issues statement paper on liquid biopsy for lung cancer

June 21, 2018, International Association for the Study of Lung Cancer

The lungs can be a difficult organ to biopsy with a needle, so the promise of identifying lung cancer through a blood-based biopsy has lung cancer experts and patients optimistic. Knowing how and when to use a liquid biopsy is critically important and led global experts at the International Association for the Study of Lung Cancer (IASLC) to issue "The IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)," now available online in the Journal of Thoracic Oncology.

"Liquid biopsy and its subsequent molecular analysis is a powerful tool that can determine the patient's molecular tumor profile in order to determine the best therapeutic option and can be applied as an alternative to tissue testing in cases where tumor testing is not possible or tissue is not adequate," said Fred R. Hirsch, MD, Ph.D., and CEO of the IASLC. "Gathering experts to collect and interpret a vast amount of information and to distribute best practices ensures that general oncologists and clinicians have access to the latest and best information in the emerging field of liquid biopsies."

Historically, tissue biopsy specimens have been the sole source of tumor molecular information, but unfortunately, adequate tissue is not always easy to obtain from all with advanced NSCLC. In addition, the need to monitor responses to treatment and to identify emergent molecular mechanisms of resistance are increasingly important but are limited by the challenges of traditional tissue rebiopsies. In this context, the isolation of tumor-derived DNA, RNA and cells from the peripheral circulation (a concept termed liquid biopsy) is emerging as a versatile and powerful tool for the optimization of NSCLC clinical management via the identification of predictive biomarkers, either prior to treatment or at progression.

In just the past decade, tremendous advances in the treatment of metastatic non-small cell (NSCLC) have been made due to the identification of targetable oncogenic molecular drivers on which the tumors are dependent for their growth and survival. Precision oncology—treating the patient with therapies predicted to be effective based on the specific molecular characteristics of their tumor—can add years of quality life for those patients. Ensuring that oncologists worldwide have access to these advances is critical to ensuring that all patients have access to the latest treatments.

For this reason, the International Association for the Study of Lung Cancer (IASLC) convened a multidisciplinary panel of thoracic oncology experts with interest and expertise in liquid biopsy and molecular pathology to evaluate currently available evidence with the aim of producing a set of recommendations for the use of liquid for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs.

The possibility of using a non-invasive method to understand and identify molecular targets and mechanisms of resistance for current drugs, both targeted agents and immunotherapies, will be extremely beneficial for patients, as will harnessing these strategies to identify new biomarkers. The future of liquid biopsies is undeniably exciting, but there is a need to more clearly understand the latest developments.

Given the pace of advances in thoracic oncology, such as , collecting and distributing up-to-date information is critical to improving outcomes worldwide. The IASLC is committed to serving as a global resource for all involved in cancer, the leading cause of -related deaths worldwide.

Explore further: Scientific advances in thoracic oncology in 2016 highlighted by the IASLC

More information: Christian Rolfo et al, IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC), Journal of Thoracic Oncology (2018). DOI: 10.1016/j.jtho.2018.05.030

Related Stories

Scientific advances in thoracic oncology in 2016 highlighted by the IASLC

June 8, 2017
Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging and treatment in 2016, the International Association for the Study of Lung Cancer (IASLC) announces the second annual publication ...

Making milestones against non-small cell lung cancer

January 24, 2018
Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering ...

Liquid biopsies for identification of EGFR mutations and prediction of recurrence

July 25, 2016
Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies ...

Report: New system for more accurate cancer staging to aid precision medicine

December 11, 2017
Adding a blood test called liquid biopsy to a standard tissue biopsy could significantly improve the accuracy of diagnosis and treatment for patients with cancer, according to researchers at Wake Forest Baptist Medical Center.

Genetic profile of treatment-resistant lung cancer more variable than previously thought

March 16, 2017
The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought. Analysis of 355 biopsied tumors from patients who acquired resistance to EGFR ...

Liquid biopsy provides real-time blood test for solid lung cancer tumors

February 27, 2015
In the rapidly changing world of molecular profiling for genetic diseases, cancer researchers are increasingly optimistic about the reality of a simple blood test to monitor and treat solid tumor cancers.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.